tpi

TPI-1 is a SHP-1 inhibitor.

TPI 287 is a synthetic, third generation taxane with potential antineoplastic activity. TPI 287 binds to tubulin and stabilizes microtubules, resulting in inhibition of microtubule assembly/disassembly dynamics, cell cycle arrest at the G2/M phase, and apoptosis.

TPI-1917-49 is a promising amyloid reducing agent that works by reducing Aβ levels.

FMOC-L-1,2,3,4-TETRAHYDRONORHARMAN-3-CAR (Fmoc-Tpi-OH) is a derivative of THN.

Tianeptine (Tianeptine sodium) is a selective 5-HT uptake facilitator in vitro and in vivo.

Tipiracil hydrochloride (MA-1 hydrochloride) is a thymidine phosphorylase inhibitor (TPI). Tipiracil hydrochloride is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials.

CTPI-2 is an inhibitor of mitochondrial citrate carrier SLC25A1 with(KD : 3.5 μM). CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 exhibits anti-tumor activity.CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet.

Trifluridine tipiracil hydrochloride mixture (TAS-102) is a novel oral combination drug containing trifluridine (TFT) and tipiracil hydrochloride (TTP) in a 2:1 molar ratio.

Triosephosphate isomerase (TPI), a glycolytic enzyme, efficiently catalyzes the interconversion between dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate. The catalytic site of TPI is located at the dimer interface [1].